Kiadis Pharma was a clinical-stage biopharmaceutical company that specialized in the development of innovative cell-based immunotherapies for patients with life-threatening diseases, primarily focusing on cancer. Its core technology centered around natural killer (NK) cells, aiming to provide 'off-the-shelf' treatments. Key programs included K-NK002 for hematopoietic stem cell transplant relapse and K-NK003 for relapsed/refractory acute myeloid leukemia. In April 2021, Sanofi successfully completed the acquisition of Kiadis Pharma, integrating its NK cell technology platform and pipeline to strengthen Sanofi's immuno-oncology portfolio.
Served as the central hub for research and development, corporate operations, and clinical trial management prior to its acquisition by Sanofi.
Located within the Amsterdam Science Park, a vibrant ecosystem fostering collaboration between academia, research institutes, and innovative companies.
As a clinical-stage biotech, the culture was likely characterized by innovation, scientific rigor, a fast-paced environment, and a strong focus on patient outcomes. Collaboration and adaptability would have been key.
The Amsterdam headquarters was pivotal for Kiadis's development of its NK cell platform and advancing its clinical programs towards potential commercialization.
Prior to its acquisition by Sanofi, Kiadis Pharma's global presence was primarily driven by its clinical trial operations, which spanned multiple countries in Europe and North America. The company also engaged in global collaborations and partnerships. Following the acquisition, Kiadis's technology and assets became part of Sanofi's extensive global R&D, manufacturing, and commercial network, significantly expanding the potential reach of its NK cell platform.
Science Park 406
Amsterdam
North Holland
Netherlands
Address: Undisclosed (Likely a small presence for US operations/partnerships)
To facilitate engagement with the U.S. Food and Drug Administration (FDA), access to U.S. clinical trial sites, and interaction with the North American investment community and potential pharmaceutical partners.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kiadis Pharma' leadership includes:
Kiadis Pharma has been backed by several prominent investors over the years, including:
With the completion of Sanofi's acquisition of Kiadis Pharma in April 2021, the existing Kiadis Pharma executive team was dissolved as the company's operations and personnel were integrated into Sanofi. Key leadership roles transitioned as part of this integration.
Discover the tools Kiadis Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Sanofi, Kiadis Pharma likely used common corporate email formats. Based on typical naming conventions, the most probable formats would have been [first_initial][last]@kiadis.com or [first].[last]@kiadis.com. These email addresses are no longer active.
f[last]@kiadis.com (e.g., jdoe@kiadis.com) or [first].[last]@kiadis.com (e.g., jane.doe@kiadis.com)
Format
a.lahr@kiadis.com (Hypothetical example based on former CEO and common format)
Example
0%
Success rate
Sanofi Press Release • April 16, 2021
Sanofi announced today the successful completion of its acquisition of Kiadis Pharma N.V. (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative ‘off-the-shelf’ natural killer (NK) cell-based medicines for the treatment of patients with life-threatening diseases. Kiadis’ proprietary platform is based on allogeneic NK cells from a healthy donor....more
Kiadis Pharma Press Release (Archived/Reported) • December 18, 2020
Kiadis Pharma N.V. announced that during the extraordinary general meeting of shareholders (EGM) held today, Kiadis shareholders approved the acquisition of Kiadis by Sanofi. This paved the way for Sanofi's acquisition of the company....more
Sanofi Press Release • November 2, 2020
Sanofi announced it would acquire Kiadis for €5.45 per share, valuing the company at approximately €308 million. The acquisition aimed to bolster Sanofi's immuno-oncology pipeline with Kiadis's NK cell technology platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kiadis Pharma, are just a search away.